Volume 26, Issue 123, May 2022

Prognostic value of serum free light chain at diagnosis of multiple myeloma

Phan Nguyen Thanh Van^1♦, Cao Thi Loc²

¹Department of Biochemistry, Pham Ngoc Thach University of Medicine, Ho Chi Minh city, Vietnam
²Adult Hematology Department no.1, Ho Chi Minh City Hospital of Hematology and Blood Transfusion, Vietnam

^♦Corresponding author
Department of Biochemistry, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam

ABSTRACT

Purposes: To determine the prognostic value of serum free light chain (sFLC) at the diagnosis for patients with multiple myeloma at Ho Chi Minh City Hospital of Hematology and Blood Transfusion. Methods: A retrospective study was carried out on 74 patients who were diagnosed with multiple myeloma at Ho Chi Minh City Hospital of Hematology and Blood Transfusion from January 2019 to December 2021. Results: Three-year OS of patients in the low sFLCR group was higher than that in the high sFLCR group (96.7% vs. 74.7%, respectively). Median survival time of patient with low sFLCR was 21.5 months while 16.5 months in the high sFLCR group. Three-year PFS of the low sFLCR group was higher than that in the high sFLCR group (87.2% vs. 64.2%, respectively). The median progression-free survival time in the high sFLCR group and low sFLCR group was 16.5 months and 19 months, respectively. The difference of OS and PFS among 3 groups NSS1, 2 and 3 was not significant. However, the 3-year PFS among the NSS-1 and NSS-3 groups was significant when considering each group separately. Conclusion: Serum free light chain at diagnosis is a good marker to predict the outcomes of myeloma patients.

Keywords: sFLC, multiple myeloma, OS, PFS

Medical Science, 2022, 26, ms192e2292

PDF

DOI: https://doi.org/10.54905/disssi/v26i123/ms192e2292

Published: 27 May 2022